Allgenesis Biotherapeutics Australia

Allgenesis Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to the research and development of novel ophthalmic drugs. The company's lead candidate, AG-73305, is a first-in-class bispecific fusion protein designed to treat diabetic macular edema and neovascular age-related macular degeneration by simultaneously inhibiting VEGF and PDGF pathways. Allgenesis also maintains a robust pipeline featuring AG-80308, a small molecule agonist for dry eye disease, and AG-929 for glaucoma. With operations spanning Taiwan, the United States, and Australia, the company focuses on addressing significant unmet needs in vision-threatening eye diseases. Their approach combines deep expertise in ophthalmology with innovative drug design to create long-acting and highly effective therapeutic solutions.